FDA Requests More Data for Needle-Free Epinephrine Alternative
The US Food and Drug Administration (FDA) has declined to approve a needle-free epinephrine nasal spray for the treatment of severe allergic reactions. The FDA requested more data from drugmaker ARS Pharmaceuticals, including a study on repeat doses. The decision comes despite a positive recommendation from an independent advisory committee. If approved, the nasal spray, called Neffy, would be the first needle-free epinephrine treatment. The FDA's decision has disappointed patient advocacy groups who believe a nasal spray option would provide more options and be easier to use for people with severe allergies. ARS Pharmaceuticals plans to resubmit the necessary data in the first half of 2024.
- FDA declines to approve needle-free epinephrine, asks drugmaker for more data CNN
- FDA rejects first needle-free alternative to EpiPens, calling for additional research NBC News
- FDA weighs nasal spray alternative to EpiPen CBS News
- FDA declines approval of needle-free EpiPen alternative, wants more data AOL
- FDA rejects needle-free alternative to EpiPen NBC News
Reading Insights
0
3
4 min
vs 5 min read
87%
841 → 106 words
Want the full story? Read the original article
Read on CNN